Cancers utilize these immune checkpoints as an escape mechanism by binding to the CTLA-4 and PD receptors more competitively and stronger, thus inhibiting the cytotoxic T-Cell and immune response and avoiding detection and/or destruction by the immune system (30). Here, CTLA4 is linked to cancer.